RAK MHSU Banner image
Dr. Walaa Baderaldeen Ibraheem Alshaikh Profile Picture

Dr. Walaa Baderaldeen Ibraheem Alshaikh

Assistant Professor – Medicinal Chemistry

Qualifications
  • Ph.D., Medicinal Chemistry, September 2021. University de Tours, France.
  • Master of Pharmacy in Medicinal Chemistry, March 2016. University of Gezira, Faculty of Pharmacy, Sudan.
  • Bachelor of Pharmacy, March 2010. University of Gezira, Faculty of Pharmacy, Sudan.
Experience
  • Assistant professor of pharmaceutical chemistry, RACOP, UMHSU, from September 2024-present.
  • Assistant professor of pharmaceutical chemistry, Faculty of Pharmacy, University of Gezira, Sudan, from September 2021-September 2024.
  • Lecturer of pharmaceutical chemistry, Faculty of Pharmacy, University of Gezira, Sudan, from April 2016-September 2021.
  • Teaching Assistant of pharmaceutical chemistry, Faculty of Pharmacy, University of Gezira, Sudan, from December 2015-April 2016.
Courses Taught
  • Innovations & Entrepreneurship in Pharmacy (PIE503)
  • General Chemistry for Pharmacy (PGC-103P)
  • Pharmaceutical Calculations (PPC203)
  • Pharmaceutical Analysis-1 (PRA213)
Publications
  • Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
  • Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.
  • Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Studies.
  • Insights into the Inhibition of Mycolic Acid Synthesis by Cytosporone E Derivatives for Tuberculosis Treatment Via an In Silico Multi-target Approach.
  • Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin's Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles.
  • Cytosporone E analogues as BRD4 inhibitors for cancer treatment: Molecular docking and molecular dynamic investigations.
  • Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MMGBSA calculations, and molecular dynamics.
  • Phthalide Derivatives as Dihydrofolate Reductase Inhibitors for Malaria: Molecular Docking and Molecular Dynamics.
  • Drug repurposing for SARS-CoV-2 main protease: Molecular docking and molecular dynamics investigations.
  • Design of Novel Coumarins as Potent Mcl-1 Inhibitors for Cancer Treatment Guided by 3D-QSAR, Molecular Docking and Molecular Dynamics.
  • Identification of Novel Transmembrane Protease Serine Type 2 Drug Candidates for COVID-19 Using Computational Studies.
  • Synthesis, antibacterial and cytotoxic evaluation of cytosporone E and analogs.
  • Synthesis and antibacterial activity of racemic paecilocin A and its derivatives against methicillin-sensitive and -resistant Staphylococcus aureus.
Achievements
  • PhD scholarship at Laboratoire Synthese et Isolement de Molecules Bioactives (SIMBA, EA 7502), University de Tours, Tours, France. Sponsored by: Ministry of Higher Education (Sudan) and French Government.